Meraz-Torres, Francisco
Niessner, Heike
Plöger, Sarah
Riel, Simon
Schörg, Barbara
Casadei, Nicolas
Kneilling, Manfred
Schaller, Martin
Flatz, Lukas
Macek, Boris
Eigentler, Thomas
Rieß, Olaf
Garbe, Claus
Amaral, Teresa
Sinnberg, Tobias http://orcid.org/0000-0003-3922-3327
Funding for this research was provided by:
Novartis Pharma (Maya 2020)
Consejo Nacional de Ciencia y Tecnología
Universitätsklinikum Tübingen
Article History
Received: 12 August 2023
Accepted: 26 December 2023
First Online: 23 January 2024
Declarations
:
: The underlying experiments were ethically approved by the local authorities. In particular, the isolation of melanoma cells from tumor tissue and the development of cell lines (PDSC) and patient-derived xenografts (PDX) were approved by the local ethics committee under license number 781/2018 BO2 and by the Regierungspräsidium under license number HT 7/18A. All animal studies with disulfiram were approved by the Regierungspräsidium Tübingen under license number HT01/20G.
: FMT, SP, SR, BS, NC, MK, MS, BM and OR have no competing interests. HN reports institutional funding from Novartis and Pierre-Fabre outside the submitted work. LF has/had advisory roles for Novartis, Sanofi, Philogen, and Bristol-Myers Squibb, all which took place outside the submitted work. TE is/was a consultant for Novartis, MSD, Merck, CureVac, Bristol-Myers Squibb, Sanofi, Immunocore, Pierre Fabre, Almirall Hermal. All out of the scope of this work. CG reports grants and personal fees from NeraCare, Novartis, Roche, Sanofi, personal fees from Amgen, BMS, MSD, and Philogen, all outside the submitted work. TA declares personal fees from CeCaVa, BMS, Novartis and Pierre Fabre and institutional grants from Novartis, Neracare, Sanofi, Novartis, Skyline-Dx, IO Biotech, MSD, University Hospital Essen, Roche and Unicancer all outside the submitted work. TS reports institutional funding from Novartis, Pascoe, Neracare and Skyline-Dx all outside the submitted work.